In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...

Abstract: Given the global coverage provided by the global navigation satellite system (GNSS) signals, the GNSS-based passive radar shows potential in maritime moving target detection. However, the ...

WhatsApp chats have become central to both our work and personal lives. After winning our trust with its end-to-end encryption feature, the app has also become a storehouse of our personal photos and ...

Abstract: Java web applications have been extensively utilized for hosting and powering high-value commercial websites. However, their intricate complexities leave them susceptible to a critical ...

Creating simple data classes in Java traditionally required substantial boilerplate code. Consider how we would represent Java’s mascots, Duke and Juggy: public class JavaMascot { private final String ...

X has yet to give any official commentary regarding the issue, though its engineers have unofficially acknowledged the problem to the security researcher. But if you've been using X long enough, you ...

Rallybio has swerved away from its Recursion Pharmaceuticals pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway to mid-2027. Exscientia, now part of ...

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. Shrinking the Salt Lake City-based company’s ...